According to Zhitong Finance App News, Weigao Co., Ltd. (01066) announced the 2026 interim results of Weigao Orthopedics (688161.SH), with operating income of about 704 million yuan, a year-on-year decrease of 4.93%; net profit attributable to shareholders of listed companies was about 132 million yuan, a year-on-year decrease of 6.85%; basic earnings per share were 0.33 yuan, with a discovery dividend of 0.90 yuan (tax included) for every 10 shares.

According to the announcement, the reason for the slight decline in revenue and net profit was mainly due to phased fluctuations in domestic terminal clinical surgery volume, increased market competition, and progress in volume procurement during the reporting period, which led to a slight decline in sales of the company's main products in the short term. However, the company's development momentum is still improving. In particular, it continues to achieve results in sports medicine production line expansion, post-investment integration of minimally invasive orthopedic production lines, overseas product registration, market expansion, and R&D innovation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.